Gynecologic Cancer 274

April 26, 2017

Sponsor: Gynecologic Oncology Group

Number: 274

Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III trials are new treatments that have worked well in a small number of patients with a disease). This trial  studies how well giving Cisplatin and radiation therapy together with or without Carboplatin and Paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Chemotherapy drugs, such as Cisplatin, Carboplatin, and Paclitaxel, work in different ways to stop the growth of cancer/tumor cells. The drugs stop the growth either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External radiation therapy uses high-energy x rays to kill cancer/tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill cancer/tumor cells. It is not yet known whether giving Cisplatin and external and internal radiation therapy together with Carboplatin and Paclitaxel kills more cancer/tumor cells.

Who’s eligible: 

  • Eligible patients will have locally advanced cervical cancer (cancer which has spread from the site of the primary /original tumor only to surrounding tissue) suitable for primary treatment with chemo-radiation with curative intent, in addition to:
    • Histological (tissue microscopically examined) diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix.
    • FIGO 2008 stage IB1 & node positive, IB2, II, IIIB, or IVA disease.
  • The Eastern Cooperative Oncology Group (ECOG) performance status must be 0-2. ECOG status is used by your doctor in order to assess how your disease is progressing, assess how the disease effects of your daily living abilities, and determine appropriate treatment and prognosis. There must be a histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix.
  • This study is for women age 18 and older.

Available at: The Hospital of Central Connecticut, Hartford Hospital.

Cancer Clinical Research Office